109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
PC/BCP 区突变对接受核苷类似物治疗的 HBeAg 阳性慢性乙型肝炎患者血清学转换及复发的影响
Authors Xia S, He X, Gan J, Ding J
Received 24 April 2025
Accepted for publication 27 October 2025
Published 14 November 2025 Volume 2025:18 Pages 5949—5959
DOI https://doi.org/10.2147/IDR.S536426
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yan Li
Shulin Xia,1,* Xiaomin He,1,* Jianhe Gan,2 Jiachen Ding1
1Department of Infectious Diseases, The Taixing People’s Hospital, Taixing City, Taizhou, Jiangsu, 225400, People’s Republic of China; 2Department of Infectious Disease, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiachen Ding, Department of Infectious Diseases, The Taixing People’s Hospital, No. 1 Changzheng Road, Taixing City, Taizhou, Jiangsu, 225400, People’s Republic of China, Tel/Fax +86 18762330668, Email dingjiachendjc@sina.com
Background: Precore/Basal core promotor (PC/BCP) mutations are critical mechanisms by which hepatitis B virus (HBV) evades host immunity and antiviral therapy. These mutations are prevalent in HBeAg-positive chronic hepatitis B (CHB) patients, potentially leading to suboptimal responses to nucleos(t)ide analogues (NAs) and high relapse risk after treatment discontinuation.
Objective: This study aimed to investigate the impact of PC/BCP mutations on seroconversion and relapse rates and analyze their association with drug resistance mechanisms. The study also evaluated the significance of mutation count (one, two, or three mutations) and specific types of mutations (A1762T, G1764A, G1896A) in relation to the seroconversion and relapse processes.
Methods: From 2016 to 2019, 48 HBeAg-positive CHB patients were collected and divided into mutation (n=37) and non-mutation (n=11) groups based on PC/BCP status. Seroconversion rates after 144 weeks of NA therapy and relapse rates after 48 weeks of treatment discontinuation were analyzed. Baseline viral load (HBV DNA), liver function (ALT), and Precore/ Basal Core Promoter (PC/BCP) mutation status were analyzed for their correlation with clinical outcomes.
Results: Among the 37 patients in the mutation group, 9 exhibited G1896A mutation, 15 exhibited A1762T/G1764A double mutations, 13 exhibited A1762T/G1764A/G1896A triple mutations. The mutation group showed significantly lower seroconversion rates than the non-mutation group (37.8% vs 81.8%, P=0.016). The seroconversion rate was inversely correlated with the number of mutations, with triple mutations (A1762T, G1764A, G1896A) associated with the lowest seroconversion rate. The mutation group exhibited a 100% relapse rate (14/14 cases) with HBeAg reactivation, while no relapses occurred in the non-mutation group (0/9 cases, P=0.0001). PC/BCP mutations (eg, A1762T/G1764A) likely reduce NA sensitivity by enhancing viral replication (upregulating pgRNA transcription) and immune evasion (HBeAg epitope variation), leading to delayed treatment response and viral rebound after discontinuation of therapy.
Conclusion: PC/BCP mutations are independent risk factors for poor NA response and high relapse rates in HBeAg-positive CHB patients. Patients with these mutations should be managed as “occult HBeAg-negative CHB” to avoid premature treatment discontinuation. Routine PC/BCP mutation testing is recommended to guide individualized treatment duration in HBeAg-positive CHB patients.
Keywords: Hepatitis B virus, PC/BCP mutations, nucleos(t)ide analogues, seroconversion, relapse
1Department of Infectious Diseases, The Taixing People’s Hospital, Taixing City, Taizhou, Jiangsu, 225400, People’s Republic of China; 2Department of Infectious Disease, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiachen Ding, Department of Infectious Diseases, The Taixing People’s Hospital, No. 1 Changzheng Road, Taixing City, Taizhou, Jiangsu, 225400, People’s Republic of China, Tel/Fax +86 18762330668, Email dingjiachendjc@sina.com
Background: Precore/Basal core promotor (PC/BCP) mutations are critical mechanisms by which hepatitis B virus (HBV) evades host immunity and antiviral therapy. These mutations are prevalent in HBeAg-positive chronic hepatitis B (CHB) patients, potentially leading to suboptimal responses to nucleos(t)ide analogues (NAs) and high relapse risk after treatment discontinuation.
Objective: This study aimed to investigate the impact of PC/BCP mutations on seroconversion and relapse rates and analyze their association with drug resistance mechanisms. The study also evaluated the significance of mutation count (one, two, or three mutations) and specific types of mutations (A1762T, G1764A, G1896A) in relation to the seroconversion and relapse processes.
Methods: From 2016 to 2019, 48 HBeAg-positive CHB patients were collected and divided into mutation (n=37) and non-mutation (n=11) groups based on PC/BCP status. Seroconversion rates after 144 weeks of NA therapy and relapse rates after 48 weeks of treatment discontinuation were analyzed. Baseline viral load (HBV DNA), liver function (ALT), and Precore/ Basal Core Promoter (PC/BCP) mutation status were analyzed for their correlation with clinical outcomes.
Results: Among the 37 patients in the mutation group, 9 exhibited G1896A mutation, 15 exhibited A1762T/G1764A double mutations, 13 exhibited A1762T/G1764A/G1896A triple mutations. The mutation group showed significantly lower seroconversion rates than the non-mutation group (37.8% vs 81.8%, P=0.016). The seroconversion rate was inversely correlated with the number of mutations, with triple mutations (A1762T, G1764A, G1896A) associated with the lowest seroconversion rate. The mutation group exhibited a 100% relapse rate (14/14 cases) with HBeAg reactivation, while no relapses occurred in the non-mutation group (0/9 cases, P=0.0001). PC/BCP mutations (eg, A1762T/G1764A) likely reduce NA sensitivity by enhancing viral replication (upregulating pgRNA transcription) and immune evasion (HBeAg epitope variation), leading to delayed treatment response and viral rebound after discontinuation of therapy.
Conclusion: PC/BCP mutations are independent risk factors for poor NA response and high relapse rates in HBeAg-positive CHB patients. Patients with these mutations should be managed as “occult HBeAg-negative CHB” to avoid premature treatment discontinuation. Routine PC/BCP mutation testing is recommended to guide individualized treatment duration in HBeAg-positive CHB patients.
Keywords: Hepatitis B virus, PC/BCP mutations, nucleos(t)ide analogues, seroconversion, relapse